menu

Loading...

NKTX Stock: Price, Forecast, Financials & AI Analysis

Loading chart...

High

2.800

Open

2.630

VWAP

2.70

Vol

775.15K

Mkt Cap

191.78M

Low

2.600

Amount

2.09M

EV/EBITDA(TTM)

--

Total Shares

71.03M

EV

-90.55M

EV/OCF(TTM)

--

P/S(TTM)

--

Nkarta, Inc. is a clinical-stage biopharmaceutical company advancing the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The Company is developing NKX019, a chimeric antigen receptor-natural killer (CAR NK) product candidate targeting the CD19 antigen for the treatment of patients with autoimmune diseases and NKX101, a CAR NK product candidate targeting cells that display NKG2D ligands. NKX019 is engineered with a humanized CD19-directed CAR for enhanced cell targeting and a proprietary, membrane-bound form of interleukin-15 (IL-15) for greater persistence and activity without exogenous cytokine support. CD19 is a biomarker for normal B cells as well as those implicated in autoimmune disease and B cell-derived malignancies. Its NKX019 autoimmune program is based on the potential to eliminate the pathologic B cells that produce autoantibodies.

Show More

Events Timeline

(ET)

2025-11-10

16:04:10

Nkarta Announces Q3 Earnings Per Share of 29 Cents, Below Consensus Estimate of 30 Cents

2025-08-12 (ET)

2025-08-12

16:05:27

Nkarta reports Q2 EPS (31c), consensus (35c)

2025-06-09 (ET)

2025-06-09

16:15:10

Lyell Immunopharma appoints David Shook as CMO, Mark Meltz as general counsel

2025-06-06 (ET)

2025-06-06

08:57:18

Nkarta appoints Shawn Rose as CMO, head of R&D

2025-05-14 (ET)

2025-05-14

16:14:53

Nkarta reports Q1 EPS (43c), consensus (45c)

News

Yahoo Finance

01-21Yahoo Finance

ImmunityBio Shares Triple in Three Weeks, Short-Sellers Face $500 Million Loss

Globenewswire

2025-12-02Globenewswire

Nkarta (NKTX) Participates in Evercore 8th Annual Healthcare Conference to Showcase NK Cell Therapy Progress

Newsfilter

2025-10-30Newsfilter

Nkarta to Attend Investor Conferences in November

Newsfilter

2025-10-22Newsfilter

Nkarta to Present Poster at the Upcoming American College of Rheumatology (ACR) Convergence Meeting

NASDAQ.COM

2025-08-13NASDAQ.COM

Nkarta Posts Narrower Loss in Q2

Benzinga

2025-08-13Benzinga

Needham Reiterates Buy on Nkarta, Maintains $10 Price Target

5 Analyst Rating

Wall Street analysts forecast NKTX stock price to rise

4 Buy

1 Hold

0 Sell

Strong Buy

Current: 0.000

Low

10.00

Averages

12.33

High

16.00

Current: 0.000

Low

10.00

Averages

12.33

High

16.00

Stifel

Buy

downgrade

$12 -> $11

AI Analysis

2025-11-11

Reason

Stifel

Price Target

$12 -> $11

AI Analysis

2025-11-11

downgrade

Buy

Reason

Stifel lowered the firm's price target on Nkarta to $11 from $12 and keeps a Buy rating on the shares. The firm believes management's decision to forego a preliminary year-end 2025 data disclosure and instead guide to the presentation of a more-fulsome data set at a FY26 medical conference should remove a near-term overhang given the former disclosure format was perceived to be mostly inconclusive, the analyst tells investors following the Q3 update.

Stifel

Stephen Willey

Buy

downgrade

$14 -> $12

2025-08-14

Reason

Stifel

Stephen Willey

Price Target

$14 -> $12

2025-08-14

downgrade

Buy

Reason

Stifel analyst Stephen Willey lowered the firm's price target on Nkarta to $12 from $14 and keeps a Buy rating on the shares. The recent earnings announcement and corporate update did not provide "any incremental surprises" as management is still guiding to the disclosure of preliminary data from the Ntrust-1/2 trials evaluating NKX019 in autoimmune disease before year-end, the analyst tells investors. The firm's reduced price target mostly reflects revised longer-term financing assumptions and valuation, the analyst noted.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for NKTX

Unlock Now

Valuation Metrics

The current forward P/E ratio for Nkarta Inc (NKTX.O) is -1.47, compared to its 5-year average forward P/E of -4.06. For a more detailed relative valuation and DCF analysis to assess Nkarta Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

dotted line Image

N/A

5Y Average PE

-4.06

Current PE

-1.47

Overvalued PE

-0.60

Undervalued PE

-7.52

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

dotted line Image

N/A

5Y Average EV/EBITDA

-1.00

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

1.14

Undervalued EV/EBITDA

-3.14

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

dotted line Image

N/A

5Y Average PS

0.00

Current PS

0.00

Overvalued PS

0.00

Undervalued PS

0.00

Financials

AI Analysis

Annual

Quarterly

Whales Holding NKTX

RA Capital Management, L.P.

New Enterprise Associates, Inc.

Trading Trends

People Also Watch

Frequently Asked Questions

What is Nkarta Inc (NKTX) stock price today?

The current price of NKTX is 2.7 USD — it has increased 0

What is Nkarta Inc (NKTX)'s business?

Nkarta, Inc. is a clinical-stage biopharmaceutical company advancing the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The Company is developing NKX019, a chimeric antigen receptor-natural killer (CAR NK) product candidate targeting the CD19 antigen for the treatment of patients with autoimmune diseases and NKX101, a CAR NK product candidate targeting cells that display NKG2D ligands. NKX019 is engineered with a humanized CD19-directed CAR for enhanced cell targeting and a proprietary, membrane-bound form of interleukin-15 (IL-15) for greater persistence and activity without exogenous cytokine support. CD19 is a biomarker for normal B cells as well as those implicated in autoimmune disease and B cell-derived malignancies. Its NKX019 autoimmune program is based on the potential to eliminate the pathologic B cells that produce autoantibodies.

What is the price predicton of NKTX Stock?

Wall Street analysts forecast NKTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NKTX is12.33 USD with a low forecast of 10.00 USD and a high forecast of 16.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Nkarta Inc (NKTX)'s revenue for the last quarter?

Nkarta Inc revenue for the last quarter amounts to 0.00 USD, decreased

What is Nkarta Inc (NKTX)'s earnings per share (EPS) for the last quarter?

Nkarta Inc. EPS for the last quarter amounts to -0.29 USD, decreased -25.64

How many employees does Nkarta Inc (NKTX). have?

Nkarta Inc (NKTX) has 157 emplpoyees as of March 03 2026.

What is Nkarta Inc (NKTX) market cap?

Today NKTX has the market capitalization of 191.78M USD.